🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Cholecalciferol

    Hospital Authority, Hong Kong

    Hematologic Neoplasms

    phase 2 small molecule active

    1 trial

  2. Ciclosporin

    United Therapeutics Europe Ltd

    Myocardial Reperfusion Injury

    phase 2 small molecule completed

    1 trial

  3. Cisplatin

    Ultragenyx UK Limited

    Squamous Cell Carcinoma of the Anus

    phase 2 small molecule active

    1 trial

  4. Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  5. Cisplatin Accord Healthcare 1 mg/ml concentraat voor oplossing voor infusie, Carboplatin Accord Healthcare 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Vulvar cancer

    phase 2 small molecule active

    1 trial

  6. Cisplatin and Doxorubicin

    Chinese University of Hong Kong

    Gastric Cancer Peritoneal Metastases

    phase 2 small molecule active

    1 trial

  7. Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasm

    phase 2 small molecule active

    1 trial

  8. Cisplatin+Capecitabine+Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  9. Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, DOXORUBICINA ACCORD HEALTHCARE ITALIA 2 mg/ml concentrato per soluzione per infusione

    Sana Biotechnology

    Pleural carcinosis

    phase 2 small molecule active

    1 trial

  10. Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP, JNJ-64407564, JNJ-64407564, Clonazepam Orally Disintegrating Tablets, USP, Pregabalin-ratiopharm® 25 mg Hartkapseln, Pregabalin-ratiopharm® 50 mg Hartkapseln, Clonazepam Orally Disintegrating Tablets, USP, DEXAMETHASONE ELIXIR, USP, Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP

    Janssen-Cilag International N.V.

    multiple myeloma

    phase 2 small molecule active

    1 trial

  11. Clostridium Butyricum Tablets

    The First People's Hospital of Lianyungang

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 2 small molecule active

    1 trial

  12. Cohort A: vilobelimab

    Edesa Biotech

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    2 trials

  13. Cohort B: paridiprubart

    Edesa Biotech

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    1 trial

  14. Cohort C: bevacizumab

    Edesa Biotech

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    1 trial

  15. Colchicine 0.5mg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cerebral Amyloid Angiopathy

    phase 2 small molecule active

    1 trial

  16. Cold Stored Platelets (CSP)

    United Therapeutics Europe Ltd

    Trauma

    phase 2 mab completed

    1 trial

  17. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  18. Combination of Bortezomib, Fludarabine and Cyclophosphamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mantle Cell Lymphoma Recurrent

    phase 2 small molecule active

    1 trial

  19. Combination therapy (COMB)

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  20. Combinations

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  21. Comirnaty JN.1 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, LVT-001

    Tour Hekla

    Healthy volunteers

    phase 2 small molecule active

    1 trial

  22. Conventional Roux-en-Y Gastrojejunostomy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  23. Coriolus Versicolor

    Hospital Authority, Hong Kong

    Carcinoma

    phase 2 small molecule terminated

    1 trial

  24. Cotellic 20 mg film-coated tablets, Ginisortamab

    Ningbo Cancer Hospital

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources